Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Macular Layer Thickness with Spectral-Domain and High-Resolution OCT.

Ophthalmology science·2026
Same author

Assessing referral quality in glaucoma care: a retrospective analysis of clinical data in optometrist and ophthalmologist referrals.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Association between body composition, knee synovial effusion, and serum glutamate in middle-aged women with knee osteoarthritis: a cross-sectional study.

Scientific reports·2026
Same author

Transscleral Micropulse Cyclophotocoagulation for the Treatment of Refractory Primary Congenital Glaucoma: A Case Series.

Cureus·2026
Same author

Estimation of glaucomatous impairment in the visual field, excluding the effect of posterior capsule opacification.

Scientific reports·2026
Same author

A 481-meter-high landslide-tsunami in a cruise ship-frequented Alaska fjord.

Science (New York, N.Y.)·2026

Related Experiment Video

Updated: Jul 8, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

Value of 10-2 Visual Field Testing for Detecting Progression in Patients with Glaucoma.

Ryo Tomita1, Dominique Salh1, Oksana M Dyachok1

  • 1Department of Ophthalmology and Visual Sciences, Dalhousie University and Nova Scotia Health, Halifax, Nova Scotia, Canada.

Ophthalmology
|July 6, 2026
PubMed
Summary

The 10-2 test of the Humphrey Field Analyzer offers value in detecting early glaucoma progression, particularly for patients with worse baseline central visual field loss. Pointwise analyses suggest its utility for identifying faster progression risks.

Keywords:
10-2 test24-2 testGlaucomaPerimetryProgressionReceiver operating characteristics curve analysisSensitivitySpecificityVisual Field

More Related Videos

Motion-Acuity Test for Visual Field Acuity Measurement with Motion-Defined Shapes
06:25

Motion-Acuity Test for Visual Field Acuity Measurement with Motion-Defined Shapes

Published on: February 23, 2024

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Related Experiment Videos

Last Updated: Jul 8, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

Motion-Acuity Test for Visual Field Acuity Measurement with Motion-Defined Shapes
06:25

Motion-Acuity Test for Visual Field Acuity Measurement with Motion-Defined Shapes

Published on: February 23, 2024

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Area of Science:

  • Ophthalmology
  • Visual field testing
  • Glaucoma diagnostics

Background:

  • Glaucoma is a progressive optic neuropathy leading to visual field loss.
  • Early detection of visual field progression is crucial for timely intervention.
  • The Humphrey Field Analyzer (HFA) with 24-2 and 10-2 test patterns is used for visual field assessment.

Purpose of the Study:

  • To evaluate the diagnostic value of the Humphrey Field Analyzer 10-2 test in detecting visual field progression in early glaucoma.
  • To compare the efficacy of the 10-2 test versus the 24-2 test in identifying glaucoma progression.

Main Methods:

  • A prospective longitudinal study included 96 glaucoma patients and 56 healthy controls.
  • Participants underwent Humphrey Field Analyzer 24-2 and 10-2 tests every 4 months.
  • Global, quadrant, and pointwise mean deviation (MD) slopes were computed, and progression was defined by various slope cut-offs.

Main Results:

  • No significant difference in Area Under the Curve (AUC) for global or quadrant MD slopes between the 10-2 and 24-2 tests.
  • At 90% specificity, only 53% overlap in patients classified as progressing using global MD slopes.
  • The 10-2 test showed significantly higher AUC for pointwise progression when cut-offs were ≤ -1.25 dB/y, especially in patients with worse baseline central visual field loss.

Conclusions:

  • The 10-2 test provides limited additional value over the 24-2 test for global and sectoral visual field progression analysis in early glaucoma.
  • Pointwise analysis with the 10-2 test is valuable for monitoring patients at risk of faster progression, particularly those with existing central visual field defects.